Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 7/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096864 | 0.92 | DPP4 (0.45) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2092621 | 0.91 | CHRM1 (0.48) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2094103 | 0.89 | DPP4 (0.48) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2097315 | 0.88 | LMNA (0.46) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2094219 | 0.88 | LMNA (0.48) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2095372 | 0.87 | DPP4 (0.46) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2095977 | 0.87 | DPP4 (0.43) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2093967 | 0.86 | LMNA (0.46) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2092645 | 0.86 | LMNA (0.46) | DPP4LMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2094302 | 0.86 | LMNA (0.45) | DPP4LMNACYP2C9ATP6V1B2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | DPP4 443/4885LMNA 2661/4885CYP2C9 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.